866-997-4948(US-Canada Toll Free)

Metastatic Colorectal Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Jul 2014

Category :

Cancer

No. of Pages : 424 Pages

Metastatic Colorectal Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Metastatic Colorectal Cancer - Pipeline Review, H2 2014, provides an overview of the Metastatic Colorectal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Colorectal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Metastatic Colorectal Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Metastatic Colorectal Cancer - Overview 12
Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis 13
Metastatic Colorectal Cancer - Therapeutics under Development by Companies 14
Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 19
Metastatic Colorectal Cancer - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Metastatic Colorectal Cancer - Products under Development by Companies 23
Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes 28
Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development 29
Bristol-Myers Squibb Company 29
Boehringer Ingelheim GmbH 30
F. Hoffmann-La Roche Ltd. 31
Amgen Inc. 32
AstraZeneca PLC 33
Eli Lilly and Company 34
Genentech, Inc. 35
Bavarian Nordic A/S 36
Merck & Co., Inc. 37
Takeda Pharmaceutical Company Limited 38
Celltrion, Inc. 39
Millennium Pharmaceuticals, Inc. 40
Novartis AG 41
Biocon Limited 42
Nippon Kayaku Co., Ltd. 43
Pfizer Inc. 44
Astex Pharmaceuticals, Inc. 45
Taiho Pharmaceutical Co., Ltd. 46
Teva Pharmaceutical Industries Limited 47
Exelixis, Inc. 48
Celgene Corporation 49
Bayer AG 50
Incyte Corporation 51
Merck KGaA 52
Alchemia Limited 53
Immunomedics, Inc. 54
Oncolytics Biotech Inc. 55
Regeneron Pharmaceuticals, Inc. 56
Mologen AG 57
Synta Pharmaceuticals Corp. 58
Panacea Biotec Limited 59
Morphotek, Inc. 60
Actinium Pharmaceuticals, Inc. 61
Glycotope GmbH 62
Hutchison MediPharma Limited 63
immatics biotechnologies GmbH 64
MacroGenics, Inc. 65
TetraLogic Pharmaceuticals 66
Merrimack Pharmaceuticals, Inc. 67
Syndax Pharmaceuticals, Inc. 68
Globeimmune, Inc. 69
AB Science 70
CureTech Ltd. 71
Biothera, Inc. 72
Medical Enzymes AG 73
Oncozyme Pharma Inc. 74
Genor BioPharma Co., Ltd. 75
RadioRx, Inc. 76
Karyopharm Therapeutics, Inc. 77
Immodulon Therapeutics Ltd. 78
Inbiopro Solutions Pvt. Ltd. 79
Kadmon Corporation, LLC 80
Epirus Biopharmaceuticals, Inc. 81
AlphaMab Co., Ltd 82
Metastatic Colorectal Cancer - Therapeutics Assessment 83
Assessment by Monotherapy Products 83
Assessment by Combination Products 84
Assessment by Target 85
Assessment by Mechanism of Action 91
Assessment by Route of Administration 97
Assessment by Molecule Type 99
Drug Profiles 102
panitumumab - Drug Profile 102
regorafenib - Drug Profile 105
irinotecan hydrochloride - Drug Profile 107
ramucirumab - Drug Profile 109
(tipiracil + trifluridine) - Drug Profile 114
MGN-1703 - Drug Profile 116
masitinib - Drug Profile 118
(tegafur + gimeracil + oteracil) - Drug Profile 121
etirinotecan pegol - Drug Profile 124
Novaferon - Drug Profile 127
trebananib - Drug Profile 129
entinostat - Drug Profile 133
abituzumab - Drug Profile 137
MK-2206 - Drug Profile 139
sorafenib tosylate - Drug Profile 142
axitinib - Drug Profile 146
gedatolisib - Drug Profile 149
selumetinib sulfate - Drug Profile 151
SGI-110 - Drug Profile 154
HMPL-013 - Drug Profile 157
IMA-910 - Drug Profile 158
futuximab - Drug Profile 160
ganitumab - Drug Profile 162
paclitaxel - Drug Profile 165
pimasertib hydrochloride - Drug Profile 168
ganetespib - Drug Profile 170
ruxolitinib phosphate - Drug Profile 174
pelareorep - Drug Profile 178
ontuxizumab - Drug Profile 182
nintedanib - Drug Profile 184
GlutaDON - Drug Profile 187
pentamidine isethionate - Drug Profile 189
pidilizumab - Drug Profile 191
GI-4000 - Drug Profile 193
buparlisib hydrochloride - Drug Profile 195
NK-012 - Drug Profile 199
imgatuzumab - Drug Profile 201
duligotuzumab - Drug Profile 203
Monoclonal Antibody Conjugate Targeting CEA for Metastatic Liver and Colorectal Cancer - Drug Profile 205
birinapant - Drug Profile 206
IMMU-130 - Drug Profile 208
IMM-101 - Drug Profile 209
RRx-001 - Drug Profile 210
Imprime PGG - Drug Profile 212
Cell Therapy for Metastatic Colorectal Cancer - Drug Profile 216
CV-301 - Drug Profile 217
RG-7221 - Drug Profile 218
rilotumumab - Drug Profile 219
fluorouracil - Drug Profile 221
sapitinib - Drug Profile 222
pexastimogene devacirepvec - Drug Profile 224
CEP-32496 - Drug Profile 226
BYL-719 - Drug Profile 227
Enadenotucirev - Drug Profile 229
encorafenib - Drug Profile 231
Vaccine for Metastatic Colorectal Cancer - Drug Profile 232
RXDX-101 - Drug Profile 233
Stem Cell Therapy for Oncology - Drug Profile 235
motesanib diphosphate - Drug Profile 236
cetuximab biobetter - Drug Profile 240
cabozantinib s-malate - Drug Profile 241
irinotecan sucrosofate liposomal - Drug Profile 244
TF-2 - Drug Profile 246
erismodegib - Drug Profile 248
PF-03446962 - Drug Profile 251
urelumab - Drug Profile 252
luminespib - Drug Profile 254
Monoclonal Antibody Conjugate Targeting CEA for Metastatic Liver and Colorectal Cancer - Drug Profile 257
ziv-aflibercept - Drug Profile 259
PD-0325901 + PF-05212384 - Drug Profile 263
MK-8353 - Drug Profile 264
selinexor - Drug Profile 265
bevacizumab biosimilar - Drug Profile 267
bevacizumab biosimilar - Drug Profile 268
bevacizumab biosimilar - Drug Profile 269
cetuximab biosimilar - Drug Profile 270
bevacizumab biosimilar - Drug Profile 271
IBPM-002BZ - Drug Profile 272
Actimab-C - Drug Profile 273
MLN-0264 - Drug Profile 274
bevacizumab biosimilar - Drug Profile 275
bevacizumab biosimilar - Drug Profile 276
cetuximab biosimilar - Drug Profile 277
bevacizumab biosimilar - Drug Profile 278
bevacizumab biosimilar - Drug Profile 279
MGD-007 - Drug Profile 280
cetuximab biosimilar - Drug Profile 281
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 282
cetuximab biosimilar - Drug Profile 283
bevacizumab biosimilar - Drug Profile 284
Monoclonal Antibody to Inhibit VEGFR-2 for Colorectal Cancer - Drug Profile 285
Metastatic Colorectal Cancer - Recent Pipeline Updates 286
Metastatic Colorectal Cancer - Dormant Projects 405
Metastatic Colorectal Cancer - Discontinued Products 407
Metastatic Colorectal Cancer - Product Development Milestones 408
Featured News & Press Releases 408
Appendix 417
Methodology 417
Coverage 417
Secondary Research 417
Primary Research 417
Expert Panel Validation 417
Contact Us 418
Disclaimer 418

List of Tables
Number of Products under Development for Metastatic Colorectal Cancer, H2 2014 18
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H2 2014 19
Number of Products under Development by Companies, H2 2014 21
Number of Products under Development by Companies, H2 2014 (Contd..1) 22
Number of Products under Development by Companies, H2 2014 (Contd..2) 23
Number of Products under Development by Companies, H2 2014 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2014 25
Comparative Analysis by Late Stage Development, H2 2014 26
Comparative Analysis by Clinical Stage Development, H2 2014 27
Comparative Analysis by Early Stage Development, H2 2014 28
Products under Development by Companies, H2 2014 29
Products under Development by Companies, H2 2014 (Contd..1) 30
Products under Development by Companies, H2 2014 (Contd..2) 31
Products under Development by Companies, H2 2014 (Contd..3) 32
Products under Development by Companies, H2 2014 (Contd..4) 33
Products under Investigation by Universities/Institutes, H2 2014 34
Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 35
Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 36
Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 37
Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H2 2014 38
Metastatic Colorectal Cancer - Pipeline by AstraZeneca PLC, H2 2014 39
Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H2 2014 40
Metastatic Colorectal Cancer - Pipeline by Genentech, Inc., H2 2014 41
Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 42
Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H2 2014 43
Metastatic Colorectal Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 44
Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H2 2014 45
Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 46
Metastatic Colorectal Cancer - Pipeline by Novartis AG, H2 2014 47
Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H2 2014 48
Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H2 2014 49
Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H2 2014 50
Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 51
Metastatic Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 52
Metastatic Colorectal Cancer - Pipeline by Teva Pharmaceutical Industries Limited., H2 2014 53
Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H2 2014 54
Metastatic Colorectal Cancer - Pipeline by Celgene Corporation, H2 2014 55
Metastatic Colorectal Cancer - Pipeline by Bayer AG, H2 2014 56
Metastatic Colorectal Cancer - Pipeline by Incyte Corporation, H2 2014 57
Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H2 2014 58
Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H2 2014 59
Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H2 2014 60
Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 61
Metastatic Colorectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 62
Metastatic Colorectal Cancer - Pipeline by Mologen AG, H2 2014 63
Metastatic Colorectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 64
Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H2 2014 65
Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H2 2014 66
Metastatic Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 67
Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H2 2014 68
Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2014 69
Metastatic Colorectal Cancer - Pipeline by immatics biotechnologies GmbH, H2 2014 70
Metastatic Colorectal Cancer - Pipeline by MacroGenics, Inc., H2 2014 71
Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2014 72
Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 73
Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 74
Metastatic Colorectal Cancer - Pipeline by Globeimmune, Inc., H2 2014 75
Metastatic Colorectal Cancer - Pipeline by AB Science, H2 2014 76
Metastatic Colorectal Cancer - Pipeline by CureTech Ltd., H2 2014 77
Metastatic Colorectal Cancer - Pipeline by Biothera, Inc., H2 2014 78
Metastatic Colorectal Cancer - Pipeline by Medical Enzymes AG, H2 2014 79
Metastatic Colorectal Cancer - Pipeline by Oncozyme Pharma Inc., H2 2014 80
Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2014 81
Metastatic Colorectal Cancer - Pipeline by RadioRx, Inc., H2 2014 82
Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 83
Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2014 84
Metastatic Colorectal Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 85
Metastatic Colorectal Cancer - Pipeline by Kadmon Corporation, LLC, H2 2014 86
Metastatic Colorectal Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 87
Metastatic Colorectal Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 88
Assessment by Monotherapy Products, H2 2014 89
Assessment by Combination Products, H2 2014 90
Number of Products by Stage and Target, H2 2014 93
Number of Products by Stage and Mechanism of Action, H2 2014 99
Number of Products by Stage and Route of Administration, H2 2014 104
Number of Products by Stage and Molecule Type, H2 2014 107
Metastatic Colorectal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 292
Metastatic Colorectal Cancer - Dormant Projects, H2 2014 411
Metastatic Colorectal Cancer - Discontinued Products, H2 2014 413

List of Figures
Number of Products under Development for Metastatic Colorectal Cancer, H2 2014 18
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H2 2014 19
Number of Products under Development by Companies, H2 2014 20
Number of Products under Investigation by Universities/Institutes, H2 2014 25
Comparative Analysis by LateStage Development, H2 2014 26
Comparative Analysis by Clinical Stage Development, H2 2014 27
Comparative Analysis by Early Stage Products, H2 2014 28
Assessment by Monotherapy Products, H2 2014 89
Assessment by Combination Products, H2 2014 90
Number of Products by Top 10 Target, H2 2014 91
Number of Products by Stage and Top 10 Target, H2 2014 92
Number of Products by Top 10 Mechanism of Action, H2 2014 97
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 98
Number of Products by Top 10 Route of Administration, H2 2014 103
Number of Products by Stage and Top 10 Route of Administration, H2 2014 104
Number of Products by Top 10 Molecule Type, H2 2014 105
Number of Products by Stage and Top 10 Molecule Type, H2 2014 106

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *